← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
201	201 NeOnc Technologies NTHI $79.2M	21	-6	-22%	$14.3M
202	202 Rocket One Inc RKTO $13.6M	21	+2	+11%	$1.62M
203	203 Tempest Therapeutics TPST $10.9M	21	-1	-5%	$1.44M
204	204 Allarity Therapeutics ALLR $13.5M	20	+6	+43%	$1.65M
205	205 Senti Biosciences Holdings SNTI $7.62M	20	+4	+25%	$6.37M
206	206 Briacell Therapeutics BCTX $32.6M	19	+3	+19%	$1.58M
207	207 Biofrontera BFRI $12.8M	19	+7	+58%	$2.61M
208	208 Citius Oncology CTOR $80.4M	19	+5	+36%	$9.2M
209	209 Evaxion A/S EVAX $25.5M	19	+2	+12%	$4.93M
210	210 Nanobiotix NBTX $1.12B	19	+4	+27%	$218M
211	211 AIM ImmunoTech AIM $6.68M	18	0	0%	$326K
212	212 Moleculin Biotech MBRX $8.36M	18	-2	-10%	$519K
213	213 Burning Rock Biotech BNR $168M	17	+1	+6%	$14.7M
214	214 Genprex GNPX $1.94M	17	+2	+13%	$155K
215	215 GeoVax Labs GOVX $2.1M	17	+1	+6%	$626K
216	216 Intensity Therapeutics INTS $11.6M	17	+3	+21%	$4.79M
217	217 Soligenix SNGX $7.54M	17	+2	+13%	$370K
218	218 Exicure XCUR $7.72M	17	-1	-6%	$284K
219	219 Lunai Bioworks LNAI $4.01M	16	-11	-41%	$641K
220	220 Estrella Immunopharma ESLA $13.9M	15	-1	-6%	$4.99M
221	221 BioLineRX BLRX $10.5M	14	+1	+8%	$208K
222	222 Tema Oncology ETF CANC $205M	14	+2	+17%	$20.8M
223	KAPA 223 Kairos Pharma KAPA $2.4M	14	+3	+27%	$371K
224	LIMN 224 Liminatus Pharma LIMN $4.37M	14	0	0%	$105K
225	OSRH 225 DELISTED OSR Health OSRH	14	+3	+27%	$211K